Trial Profile
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.
- 23 Jan 2017 Results assessing the feasibility and clinical outcome with intermittent sunitinib dosing in patients with metastatic renal cell carcinoma, published in the Journal of Clinical Oncology.
- 11 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.